North East and North Cumbria
ICS Formulary
4 Central nervous system
04-09-01 Dopaminergic drugs used in Parkinsons disease
Cabergoline
Formulary
Foslevidopa/foscarbidopa
Produodopa
®
Formulary
foslevidopa 240mg/foscarbidopa 12mg in 1ml solution for infusion
Approved for the treatment advanced Parkinson’s with motor symptoms in adults in line with NICE and NHSE Specialised Commissioning Policy
NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
Levidopa/carbidopa Intestinal Gel
Duodopa
®
Formulary
levidopa 20mg/carbidopa 5mg intestinal gel
Approved for the treatment of Parkinson's disease
Pramipexole (restless legs)
Formulary
Safinamide
Formulary
50mg and 100mg tablets
Approved for use in Parkinson's Disease patients on levodopa who are having motor fluctuations affecting their quality of life as an alternative to rasagiline.
Links
County Durham Shared Care Guidelines: Apomorphine
MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs
MHRA Drug Safety Update (April 2016): Apomorphine with domperidone: minimising risk of cardiac side effects
NENC Palliative and End of Life Care Symptom Control Guidelines
NICE NG42: Motor neurone disease: assessment and management
NICE NG62: Cerebral palsy in under 25s: assessment and management
NICE NG71: Parkinson’s disease in adults
NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
North of Tyne, Gateshead and North Cumbria - Apomorphine - Shared Care Guidance
South Tyneside & Sunderland APC Shared Care Guideline - Apomorphine injection or infusion for Parkinson’s disease
Tees Valley Shared Care Guidelines: Apomorphine
TEWV - Medicines Optimisation – Interactive Guide
TEWV Guidelines
TEWV Safe Transfer of Prescribing Guidance
Key
Full Site